A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

NCT00746382 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study withdrawn due to business decisions. No subjects were treated.

Conditions

Dermatitis

Interventions

DRUG: Roflumilast cream
DRUG: Placebo cream

Sponsor

AstraZeneca

Collaborators

[object Object]